Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062987 | 1.00 | GRIA1 (0.39) | GRIA1GRIA3GRIA2GRIA4CACNA1F | |
| SCHEMBL84168 | 1.00 | GRIA1 (0.39) | GRIA1GRIA3GRIA2GRIA4CACNA1F | |
| Aspartic Acid SCHEMBL5964784 | 0.79 | GRIA1 (0.43) | GRIA1GRIA3GRIA2GRIA4MEN1 | |
| SCHEMBL13319909 | 0.77 | GRIA1 (0.41) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL5290687 | 0.77 | GRIA1 (0.41) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL28471680 | 0.74 | GRIA1 (0.47) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL4437211 | 0.72 | GRIA1 (0.36) | GRIA1GRIA3GRIA2GRIA4GAA | |
| Propionic Acid SCHEMBL4774389 | 0.67 | FFAR3 (0.37) | GRIA1GRIA3GRIA2GRIA4CACNA1F | |
| (S)-Ampa SCHEMBL667915 | 0.67 | GRIA1 (0.69) | GRIA1GRIA3GRIA2GRIA4MEN1 | |
| SCHEMBL6809086 | 0.67 | CACNA1F (0.33) | CACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054463-B2 | Radiolabeled microtubule imaging compounds and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-08-06 | — | — | US | disclosed |
| US-20200290976-A1 | RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290976-A1 | RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF | TUBB3, MAP2, MAPT | GRIA1 1057/4885GRIA3 504/4885GRIA2 1075/4885 |
| US-12054463-B2 | Radiolabeled microtubule imaging compounds and uses thereof | TUBB3, MAP2, MAPT | GRIA1 1057/4885GRIA3 504/4885GRIA2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.